Jensen DE, Black AR, Swick AG, Azizkhan JC. Distinct Roles for SP1 and E2F Sites in the Growth/Cell Cycle Regulation of the DHFR Promoter. J. Cell. Biochem. 67(1):24-31, 1997

Bacchi CJ, Sanabria K, Spiess AJ, Vargas M, Marasco CJ Jr, Jiminez LM, Goldberg B, Sufrin JR. In vivo efficacies of 5’-methylthioadenosine analogs as trypanocides. Antimicrob. Agents. Chemother., 41:2108-2112, 1997

Bellnier DA, Greco WR, Parsons JC, Oseroff AR, Kuebler A, Dougherty TJ. An assay for the quantitation of Photofrin(R) in tissues and fluids. Photochem.Photobiol., 66(2):237-244, 1997

Bergeron RJ, Feng Y, Weimar WR, McManis JS, Dimova H, Porter CW, Raisler B, Phanstiel O. A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics. J.Med.Chem., 40(10):1475-1494, 1997

Berkowitz EA, Hecht CP, Azizkhan JC, Chen XR, Lee DC. Transcription factor AP2 is required for expression of the rat transforming growth factor-alpha gene. Oncogene, 14(18):2229-2238, 1997

Box HC, Maccubbin AE. Lipid peroxidation and DNA damage. Nutrition 13(10):920-921, 1997

Brucie TC, Sengupta D, Blasko A, Chiang SY, Beerman TA. A Microgonotropen Branched Decaaza Decabutylamine and its Interactions with DNA. Bioorganic Medicinal Chemistry. 5:685-692, 1997

Chiang SY, Bruice TC, Azizkhan JC, Gawron L, Beerman TA. Targeting E2F1/DNA complexes with Microgonotropen DNA binding agents. Proc. Nat. Acad. Sci., USA, 94(7):2811-2816, 1997

Cao S, Rustum YM. 5-fluorouracil prodrug, Ftorafur, modulated by uracil (UFT): preclinical and clinical prospective. Tumori, Suppl. to 83(1):S90-S93, 1997

Dolnick B. Naturally Occurring Antisense RNA. Pharmacol. & Therap., 75:1-6, 1997

Dolnick B, Lu K, Yin MB, Rustum YM. Recent Advances in the Study of rTS Proteins, rTS Expression During Growth And In Response To Thymidylate Synthase Inhibitors In Human Tumor Cells. Adv. Enzyme Regul. 37:95-109, 1997

Fogel-Petrovic M, Kramer DL, Vujcic S, Miller J, McManis JS, Bergeron RJ, Porter CW. Structural basis for differential induction of spermidine/spermine N1-acetyltransferase activity by novel spermine analogs. Mol.Pharmacol., 52(1):69-74, 1997

Frey MR, Saxon ML, Zhao X, Rollins A, Evans SS, Black JD. Protein kinase C isozyme-mediated cell cycle arrest involves induction of p21waf1/cip1 and p27kip1 and hypophosphorylation of the retinoblastoma protein in intestinal epithelial cells. J.Biol.Chem., 272(14):9424-9435, 1997

Goldberg B, Yarlett N, Sufrin JR, Lloyd D, Bacchi CJ. A unique transporter of S-adenosylmethionine in African trypanosomes. FASEB J. 11:256-260, 1997

Henderson BW, Bellnier DA, Greco WR, Sharma A, Pandey RK, Vaughan LA, Weishaupt KR, Dougherty TJ. An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy. Cancer Res., 57(18):4000-4007, 1997

Kirk C, Goodisman J, Beerman T, Gawron L, Dabrowiak J. Kinetics of cleavage of intra- and extracellular simian virus 40 DNA with the enediyne anticancer drug C-1027.. Biophysical Chemistry, 63(2-3):201-209, 1997

Kramer D, Fogel-Petrovic M, Diegelman P, Cooley JM, Bernacki RJ, McManis JM, Bergeron R, Porter CW. Effects of novel spermine analogs on cell cycle progression and apoptosis in MALME-3M human melanoma cells. Cancer Research, 57:5521-5527, 1997

Kulesz-Martin MF. Biological aspects of multistage carcinogenesis as studied in experimental animals and cell culture models. In: Molecular Mechanisms of chemical and radiation carcinogenesis, G.T. Bowden and S.M. Fischer, Eds., Vol. 10, Comprehensive Toxicology, G. Sipes, Editor-in-Chief, Pergamon Press, 1997, pp. 7-30

Levasseur LM, Greco WR, Rustum YM, Slocum HK. Combined Action of Paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma Icells. Cancer Chemotherapy & Pharm. 40:495-505, 1997

Li ZR, Hromchak R, Bloch A. Differential expression of proteins regulating cell cycle progression in growth vs differentiation. Biochim.Biophys.Acta Mol.Cell Res., 1356(2):149-159, 1997

Lu K, McGuire JJ, Slocum H, Rustum YM. Mechanisms of acquired resistance to modulation of 5-fluorouracil by leucovorin in the HCT-8 human ileocecal carcinoma cells. Biochem. Pharmacol., 53:689-696, 1997

Maccubbin AE, Mudipalli A, Nadadur SS, Ersing N, Gurtoo HL. Mutations induced in a shuttle vector plasmid exposed to monofunctionally activated Mitomycin C. Environ. Molec. Mutagenesis, 29(2):143-151, 1997

McGuire J, Magee K, Russell C, Canestrari J. Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines. Oncology Res. 9:139-147, 1997

McHugh MM, Beerman TA, Burhans WC. DNA-damaging enediyne C-1027 inhibits initiation of intracellular SV40 DNA replication in trans, Biochemistry, 36(5):1003-1009, 1997

Mihich E, Hartwell L. Meeting Report - Eighth Annual Pezoller Symposium: Genomic Instability and Immortality in Cancer. Cancer Research 57:4437-4441, 1997

Mihich E, Hartwell L. eds., Genomic Instability and Immortality in Cancer, (Eighth Annual Pezoller Symposium), Plenum Press, New York 1997

Mihich E, Nichol CA. Roswell Park Cancer Institute Symposium: Molecular Approaches to Cancer Therapeutics. (Symposium, Oct. 3-4, 1996) Cancer Research, 57:5185-5188, 1997

Miner Z, Kulesz-Martin M. DNA binding specificity of proteins derived from alternatively spliced mouse p53 mRNAs. Nucl. Acids Res. 25(7):1319-1326, 1997

Mudipalli A, Maccubbin A, Nadadur S, Struck, Gurtoo H. Mutations Induced by Monofunctional and Bifunctional Phosphoramide Mustards in SupF tRNA gene. Mutation Res., 381:49-57, 1997

Nadadur S, Lisciandro K, Mudipalli A, Maccubbin A, Faletto M, Gurtoo H. Altered biochemical profile and gene expression in aflatoxin B1-transformed C3H 10T1/2 Cells. Intl. J. Oncology 10:1265-1275, 1997

Ojima I, Kuduk SD, Pera P, Veith JM, Bernacki RJ. Synthesis and structure-activity relationships of nonaromatic taxoids: Effects of alkyl and alkenyl ester groups on cytotoxicity, J. Med.Chem., 40(3):279-285, 1997

Ojima I, Slater JC, Kuduk SD, Takeuchi CS, Gimi RH, Sun CM, Park YH, Pera P, Veith JM, Bernacki R.J. Syntheses and structure-activity relationships of taxoids derived from 14beta-hydroxy-10-deacetylbaccatin III, J.Med.Chem., 40(3):267-278, 1997

Ojima I, Slater JC, Pera P, Veith JM, Abouabdellah A, Begue JP, Bernacki RJ. Synthesis and biological activity of novel 3’-trifluoromethyl taxoids. Bioorg. Med. Chem. Lett. 7:133-138, 1997

Pajovic S, Wong EL, Black AR, Azizkhan JC. E2Fs and pocket proteins. Mol.Cell.Biol., 17(11):6459-6464, 1997

Pazdur R, Rustum YM, Villalon AH, González-Baron M. Biochemical modulation: Its pharmacological basis and clinical applications - Question and answer session, Oncology, 54, Suppl. 1:38-39, 1997

Pendyala L, Velagapudi S, Toth K, Zdanowicz J, Glaves D, Slocum H, Perez R, Huben R, Creaven P, Raghavan D. Translational studies of glutathione in bladder cancer cell lines and human specimens. 3:793-798, 1997

Pietilä M, Alhonen L, Halmekytö M, Kanter P, Jänne J, Porter CW. Activation of polyamine catabolism profoundly alters tissue polyamine pools and affects hair growth and female fertility in transgenic mice overexpressing spermidine/spermine N1-acetyltransferase, J.Biol.Chem., 272(30):18746-18751, 1997

Rustum YM. Pyrimidine Antagonist in Cancer Chemotherapy: In: Encyclopedia of CANCER, J.R. Bertino, ed., Academic Press, Vol. II G-Q, 1997, pp. 1327-1335.

Rustum YM, Harstrick A, Cao S, Vanhoefer U, Yin MB, Wilke H, Seeber S. Thymidylate synthase inhibitors in cancer therapy; direct and indirect inhibitors. J. Clin. Oncology, 15(1):389-400, 1997

Sharma A, Bernacki RJ. Commentary: Ovarian cancer patients with high CA-125 but no symptoms: Should antiangiogenic treatments be considered? Oncol. Res. 9:53-54, 1997

Sharma A, Glaves D, Porter CW, Bernacki RJ. Antitumor efficacy of N1,N11-diethylnorspermine on a human bladder tumor xenograft in nude mice. Clin. Cancer Res. 3:1239-1244, 1997

Sharma A, Mayhew E, Bolcsak L, Cavanaugh C, Harmon P, Janoff A, Bernacki RJ. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts., Intl. J. Cancer, 71(1):103-107, 1997

Tatarowicz WA, Pekosz AS, Madden SL, Rauscher FJ III, Chiang SY, Beerman TA, Fraser NW. Repression of the HSV-1 latency-associated transcript (LAT) promoter by the early growth response (EGR) proteins: Involvement of a binding site immediately downstream of the TATA box. J.Neurovirol., 3(3): 212-224, 1997

Vanhoefer U, Cao S, Harstrick A, Seeber S, Rustum YM. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Annals of Oncology, 8:1221-1228, 1997

Vanhoefer U, Yin MB, Harstrick A, Seeber S, Rustum YM. Carbamoylation of glutathione reductase by N,N-Bis(-2-chloroethyl)-N-nitrosourea associated with inhibition of multidrug resistance protein (MRP) function. Biochem. Pharm.,53(6):801-809, 1997

Varela L, Darcy K, Ip M. The epidermal growth factor receptor is not required for TNF* action in normal mammary epithelial cells. Endocrinology, 138:3891-3900, 1997

Voigt W, Vanhoefer U, Yin MB, Minderman H, Schmoll HJ, Rustum YM. Evaluation of Topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines. Anticancer Res., 17(5A):3707-3712, 1997

Weinberger M, Black L, Beerman TA, Huberman J, Burhans WC. Antitumor drugs and yeast cell cycle checkpoints. In Genomic Instability and Immortality in Cancer. Eighth Annual Pezcoller Symposia, E. Mihich and L. Hartwell, eds., Plenum Press, NY, Vol. 8 189-194, 1997

Woynarowski JM, Beerman TA. Effects of bizelesin (U-77,779), a bifunctional alkylating minor groove binder, on replication of genomic and simian virus 40 DNA in BSC-1 cells, Biochim.Biophys.Acta Gene Struct.Expression, 1353(1):50-60, 1997

Wu Y, Huang H, Miner Z, Kulesz-Martin M. Activities and Response to DNA damage of latent and active sequence-specific DNA binding forms of mouse p53 gene. Proc. Nat. Acad. Sci., USA, 94(17):8982-8987, 1997

Yin MB, Voight W, Panadero A, Vanhoefer U, Frank C, Pajovic S, Azizkhan J, Rustum YM. p53 and WAF1 are induced and Rb protein is hypophosphorylated during cell growth inhibition by the thymidylate synthase inhibitor ZD1694 (Tomudex). Mol. Pharm., 51:630-636, 1997